18F-fluciclovine PET/CT in Patients with Suspected Recurrent Prostate Cancer - Bital Savir-Baruch

Phillip Koo welcomes Bital Savir-Baruch who is presenting a review of prostate cancer imaging with 18F-FACBC fluciclovine (Axumin®) in men with suspected prostate cancer recurrence.  Dr. Baruch reviews the benefits of this technology including earlier detection of recurrent disease as compared to conventional imaging, inability of the tracer to be metabolized and the slow urinary excretion. While detection rates improve as PSA increases, there is no absolute PSA threshold for obtaining a scan.  Based on data from the LOCATE study,18F-FACBC fluciclovine scans may result in a change in the treatment strategy for 60% of patients and is therefore recommended prior to the initiation of salvage therapy. 


Bital Savir-Baruch, MD, Assistant Professor, Radiology Loyola University Medical Center Maywood, Illinois

Phillip J. Koo, MD Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona.

Read the Full Video Transcript


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.